FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 339:974-984 October 1, 1998 Number 14 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Breast cancer is a major public health problem worldwide. Management of breast cancer was last reviewed in the Journal in 1992.¹ The accumulation of new biologic information, the results of recent clinical trials, and the availability of new diagnostic and therapeutic tools make it appropriate to review the subject again.

Epidemiology

The incidence of breast cancer in the United States has been increasing gradually for the past three decades.^2,3 It was estimated that 181,600 new cases of breast cancer were diagnosed in the United States in 1997 and that 44,190 people would die of breast cancer during the same year. However, . . . [Full Text of this Article]

Biology

Diagnostic Approaches

Therapy

Primary Breast Cancer

            Local and Regional Treatment

            Axillary Lymph-Node Dissection

            Radiotherapy

            Systemic Hormone Therapy or Chemotherapy

            Preoperative Chemotherapy

            Duration of Chemotherapy

            Combination Chemotherapy and Hormone Therapy

            Dose-Intensive and High-Dose Chemotherapy Regimens

Locally Advanced and Inflammatory Breast Cancer

Metastatic Breast Cancer

            Diagnosis

            Treatment

            High-Dose Chemotherapy

Chemoprevention

Novel Therapies

Conclusions

Source Information

From the Department of Breast Medical Oncology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Box 56, Houston, TX 77030, where reprint requests should be addressed to Dr. Hortobagyi.

References

Related Letters:

Treatment of Breast Cancer
Corcoran T., Del Mastro L., Venturini M., Hortobagyi G. N.
Extract | Full Text  
N Engl J Med 1999; 340:319-320, Jan 28, 1999. Correspondence

This article has been cited by other articles:

• Suzuki, Y., Tokuda, Y., Fujiwara, Y., Iwata, H., Sasaki, Y., Saji, S., Aogi, K., Nambu, Y., Suri, A., Saeki, T., Takashima, S. (2009). Phase II Study of Gemcitabine Monotherapy as a Salvage Treatment for Japanese Metastatic Breast Cancer Patients after Anthracycline and Taxane Treatment. Jpn J Clin Oncol 39: 699-706 [Abstract] [Full Text]  
• Barrios, C. H., Sampaio, C., Vinholes, J., Caponero, R. (2009). What is the role of chemotherapy in estrogen receptor-positive, advanced breast cancer?. Ann Oncol 20: 1157-1162 [Abstract] [Full Text]  
• POLYZOS, A., GOGAS, H., MARKOPOULOS, C., TSAVARIS, N., PAPADOPOULOS, O., POLYZOS, K., GIANNOPOULOS, A. (2009). Salvage Chemotherapy with Oxaliplatin and Capecitabine for Breast Cancer Patients Pretreated with Anthracyclines and Taxanes. Anticancer Res 29: 2851-2856 [Abstract] [Full Text]  
• Li, T., Christos, P. J., Sparano, J. A., Hershman, D. L., Hoschander, S., O'Brien, K., Wright, J. J., Vahdat, L. T. (2009). Phase II trial of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205. Ann Oncol 20: 642-647 [Abstract] [Full Text]  
• Le Scodan, R., Stevens, D., Brain, E., Floiras, J. L., Cohen-Solal, C., De La Lande, B., Tubiana-Hulin, M., Yacoub, S., Gutierrez, M., Ali, D., Gardner, M., Moisson, P., Villette, S., Lerebours, F., Munck, J. N., Labib, A. (2009). Breast Cancer With Synchronous Metastases: Survival Impact of Exclusive Locoregional Radiotherapy. JCO 27: 1375-1381 [Abstract] [Full Text]  
• Michaud, L. B. (2008). Treatment-experienced breast cancer. Am J Health Syst Pharm 65: S4-S9 [Abstract] [Full Text]  
• Eckstein, N., Servan, K., Girard, L., Cai, D., von Jonquieres, G., Jaehde, U., Kassack, M. U., Gazdar, A. F., Minna, J. D., Royer, H.-D. (2008). Epidermal Growth Factor Receptor Pathway Analysis Identifies Amphiregulin as a Key Factor for Cisplatin Resistance of Human Breast Cancer Cells. J. Biol. Chem. 283: 739-750 [Abstract] [Full Text]  
• Thomas, E. S., Gomez, H. L., Li, R. K., Chung, H.-C., Fein, L. E., Chan, V. F., Jassem, J., Pivot, X. B., Klimovsky, J. V., de Mendoza, F. H., Xu, B., Campone, M., Lerzo, G. L., Peck, R. A., Mukhopadhyay, P., Vahdat, L. T., Roche, H. H. (2007). Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment. JCO 25: 5210-5217 [Abstract] [Full Text]  
• Teixeira Soares, C., Frederigue-Junior, U., de Luca, L. A. (2007). Anatomopathological Analysis of Sentinel and Nonsentinel Lymph Nodes in Breast Cancer: Hematoxylin-Eosin Versus Immunohistochemistry. INT J SURG PATHOL 15: 358-368 [Abstract]  
• Llombart-Cussac, A., Martin, M., Harbeck, N., Anghel, R. M., Eniu, A. E., Verrill, M. W., Neven, P., De Greve, J., Melemed, A. S., Clark, R., Simms, L., Kaiser, C. J., Ma, D. (2007). A Randomized, Double-Blind, Phase II Study of Two Doses of Pemetrexed as First-Line Chemotherapy for Advanced Breast Cancer. Clin. Cancer Res. 13: 3652-3659 [Abstract] [Full Text]  
• Mody, M., Dharker, N., Bloomston, M., Wang, P.-S., Chou, F.-S., Glickman, T. S, McCaffrey, T., Yang, Z., Pumfery, A., Lee, D., Ringel, M. D, Pinzone, J. J (2007). Rosiglitazone sensitizes MDA-MB-231 breast cancer cells to anti-tumour effects of tumour necrosis factor-{alpha}, CH11 and CYC202. Endocr Relat Cancer 14: 305-315 [Abstract] [Full Text]  
• Colozza, M., de Azambuja, E., Personeni, N., Lebrun, F., Piccart, M. J., Cardoso, F. (2007). Achievements in Systemic Therapies in the Pregenomic Era in Metastatic Breast Cancer. The Oncologist 12: 253-270 [Abstract] [Full Text]  
• Saeki, T., Nomizu, T., Toi, M., Ito, Y., Noguchi, S., Kobayashi, T., Asaga, T., Minami, H., Yamamoto, N., Aogi, K., Ikeda, T., Ohashi, Y., Sato, W., Tsuruo, T. (2007). Dofequidar Fumarate (MS-209) in Combination With Cyclophosphamide, Doxorubicin, and Fluorouracil for Patients With Advanced or Recurrent Breast Cancer. JCO 25: 411-417 [Abstract] [Full Text]  
• Baptista, M. Z., Prieto, V. G., Chon, S., Hortobagyi, G. N., Esteva, F. J. (2006). Tamoxifen-Related Vasculitis. JCO 24: 3504-3505 [Full Text]  
• Rapiti, E., Verkooijen, H. M., Vlastos, G., Fioretta, G., Neyroud-Caspar, I., Sappino, A. P., Chappuis, P. O., Bouchardy, C. (2006). Complete Excision of Primary Breast Tumor Improves Survival of Patients With Metastatic Breast Cancer at Diagnosis. JCO 24: 2743-2749 [Abstract] [Full Text]  
• Tanner, M., Isola, J., Wiklund, T., Erikstein, B., Kellokumpu-Lehtinen, P., Malmstrom, P., Wilking, N., Nilsson, J., Bergh, J. (2006). Topoisomerase II{alpha} Gene Amplification Predicts Favorable Treatment Response to Tailored and Dose-Escalated Anthracycline-Based Adjuvant Chemotherapy in HER-2/neu-Amplified Breast Cancer: Scandinavian Breast Group Trial 9401. JCO 24: 2428-2436 [Abstract] [Full Text]  
• Gabriel, B., Fischer, D.-C, Orlowska-Volk, M., zur Hausen, A., Schule, R., Muller, J. M., Hasenburg, A. (2006). Expression of the Transcriptional Coregulator FHL2 in Human Breast Cancer: A Clinicopathologic Study. Reproductive Sciences 13: 69-75 [Abstract]  
• Unterholzner, S., Willhauck, M. J., Cengic, N., Schutz, M., Goke, B., Morris, J. C., Spitzweg, C. (2006). Dexamethasone Stimulation of Retinoic Acid-Induced Sodium Iodide Symporter Expression and Cytotoxicity of 131-I in Breast Cancer Cells. J. Clin. Endocrinol. Metab. 91: 69-78 [Abstract] [Full Text]  
• Giacinti, L., Claudio, P. P., Lopez, M., Giordano, A. (2006). Epigenetic information and estrogen receptor alpha expression in breast cancer.. The Oncologist 11: 1-8 [Abstract] [Full Text]  
• Henriksen, T. F., Fryzek, J. P., Holmich, L. R., McLaughlin, J. K., Krag, C., Karlsen, R., Kjoller, K., Olsen, J. H., Friis, S. (2005). Reconstructive Breast Implantation After Mastectomy for Breast Cancer: Clinical Outcomes in a Nationwide Prospective Cohort Study. Arch Surg 140: 1152-1159 [Abstract] [Full Text]  
• Sarkar, D., Su, Z.-z., Vozhilla, N., Park, E. S., Gupta, P., Fisher, P. B. (2005). Dual cancer-specific targeting strategy cures primary and distant breast carcinomas in nude mice. Proc. Natl. Acad. Sci. USA 102: 14034-14039 [Abstract] [Full Text]  
• Tabuchi, M., To, H., Sakaguchi, H., Goto, N., Takeuchi, A., Higuchi, S., Ohdo, S. (2005). Therapeutic Index by Combination of Adriamycin and Docetaxel Depends on Dosing Time in Mice. Cancer Res. 65: 8448-8454 [Abstract] [Full Text]  
• Akhtar, S. S., Nadrah, H. M. (2005). Assessment of the quality of breast cancer care: a single institutional study from Saudi Arabia. Int J Qual Health Care 17: 301-305 [Abstract] [Full Text]  
• Sharma, D., Blum, J., Yang, X., Beaulieu, N., Macleod, A. R., Davidson, N. E. (2005). Release of Methyl CpG Binding Proteins and Histone Deacetylase 1 from the Estrogen Receptor {alpha} (ER) Promoter upon Reactivation in ER-Negative Human Breast Cancer Cells. Mol. Endocrinol. 19: 1740-1751 [Abstract] [Full Text]  
• Miller, K. D., Trigo, J. M., Wheeler, C., Barge, A., Rowbottom, J., Sledge, G., Baselga, J. (2005). A Multicenter Phase II Trial of ZD6474, a Vascular Endothelial Growth Factor Receptor-2 and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients with Previously Treated Metastatic Breast Cancer. Clin. Cancer Res. 11: 3369-3376 [Abstract] [Full Text]  
• Duffy, M. J. (2005). Predictive Markers in Breast and Other Cancers: A Review. Clin. Chem. 51: 494-503 [Abstract] [Full Text]  
• Liu, R., Varghese, S., Rabkin, S. D. (2005). Oncolytic Herpes Simplex Virus Vector Therapy of Breast Cancer in C3(1)/SV40 T-antigen Transgenic Mice. Cancer Res. 65: 1532-1540 [Abstract] [Full Text]  
• Duffy, C. M., Allen, S. M., Clark, M. A. (2005). Discussions Regarding Reproductive Health for Young Women With Breast Cancer Undergoing Chemotherapy. JCO 23: 766-773 [Abstract] [Full Text]  
• Miller, K. D., Chap, L. I., Holmes, F. A., Cobleigh, M. A., Marcom, P. K., Fehrenbacher, L., Dickler, M., Overmoyer, B. A., Reimann, J. D., Sing, A. P., Langmuir, V., Rugo, H. S. (2005). Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer. JCO 23: 792-799 [Abstract] [Full Text]  
• Kennedy, R. D., Quinn, J. E., Mullan, P. B., Johnston, P. G., Harkin, D. P. (2004). The Role of BRCA1 in the Cellular Response to Chemotherapy. JNCI J Natl Cancer Inst 96: 1659-1668 [Abstract] [Full Text]  
• Bernard-Marty, C., Cardoso, F., Piccart, M. J. (2004). Facts and Controversies in Systemic Treatment of Metastatic Breast Cancer. The Oncologist 9: 617-632 [Abstract] [Full Text]  
• Knostman, K. A. B., Cho, J.-Y., Ryu, K.-Y., Lin, X., McCubrey, J. A., Hla, T., Liu, C. H., Di Carlo, E., Keri, R., Zhang, M., Hwang, D. Y., Kisseberth, W. C., Capen, C. C., Jhiang, S. M. (2004). Signaling through 3',5'-Cyclic Adenosine Monophosphate and Phosphoinositide-3 Kinase Induces Sodium/Iodide Symporter Expression in Breast Cancer. J. Clin. Endocrinol. Metab. 89: 5196-5203 [Abstract] [Full Text]  
• Bishop, M. R., Fowler, D. H., Marchigiani, D., Castro, K., Kasten-Sportes, C., Steinberg, S. M., Gea-Banacloche, J. C., Dean, R., Chow, C. K., Carter, C., Read, E. J., Leitman, S., Gress, R. (2004). Allogeneic Lymphocytes Induce Tumor Regression of Advanced Metastatic Breast Cancer. JCO 22: 3886-3892 [Abstract] [Full Text]  
• Madhusudan, S., Foster, M., Muthuramalingam, S. R., Braybrooke, J. P., Wilner, S., Kaur, K., Han, C., Hoare, S., Balkwill, F., Talbot, D. C., Ganesan, T. S., Harris, A. L. (2004). A Phase II Study of Etanercept (Enbrel), a Tumor Necrosis Factor {alpha} Inhibitor in Patients with Metastatic Breast Cancer. Clin. Cancer Res. 10: 6528-6534 [Abstract] [Full Text]  
• Leonard, R. C. F., Lind, M., Twelves, C., Coleman, R., van Belle, S., Wilson, C., Ledermann, J., Kennedy, I., Barrett-Lee, P., Perren, T., Verrill, M., Cameron, D., Foster, E., Yellowlees, A., Crown, J. (2004). Conventional Adjuvant Chemotherapy Versus Single-Cycle, Autograft-Supported, High-Dose, Late-Intensification Chemotherapy in High-Risk Breast Cancer Patients: A Randomized Trial. JNCI J Natl Cancer Inst 96: 1076-1083 [Abstract] [Full Text]  
• Alexopoulos, A., Karamouzis, M. V., Stavrinides, H., Ardavanis, A., Kandilis, K., Stavrakakis, J., Georganta, C., Rigatos, G. (2004). Phase II study of pegylated liposomal doxorubicin (Caelyx(R)) and docetaxel as first-line treatment in metastatic breast cancer. Ann Oncol 15: 891-895 [Abstract] [Full Text]  
• Toth-Fejel, S., Cheek, J., Calhoun, K., Muller, P., Pommier, R. F. (2004). Estrogen and Androgen Receptors as Comediators of Breast Cancer Cell Proliferation: Providing a New Therapeutic Tool. Arch Surg 139: 50-54 [Abstract] [Full Text]  
• Baselga, J., Llombart-Cussac, A., Bellet, M., Guillem-Porta, V., Enas, N., Krejcy, K., Carrasco, E., Kayitalire, L., Kuta, M., Lluch, A., Vodvarka, P., Kerbrat, P., Namer, M., Petruzelka, L. (2003). Randomized, double-blind, multicenter trial comparing two doses of arzoxifene (LY353381) in hormone-sensitive advanced or metastatic breast cancer patients. Ann Oncol 14: 1383-1390 [Abstract] [Full Text]  
• Martin, M., Spielmann, M., Namer, M., duBois, A., Unger, C., Dodwell, D., Vodvarka, P., Lind, M., Calvert, H., Casado, A., Zelek, L., Lluch, A., Carrasco, E., Kayitalire, L., Zielinski, C. (2003). Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines. Ann Oncol 14: 1246-1252 [Abstract] [Full Text]  
• Yang, Z., Bagheri-Yarmand, R., Balasenthil, S., Hortobagyi, G., Sahin, A. A., Barnes, C. J., Kumar, R. (2003). HER2 Regulation of Peroxisome Proliferator-activated Receptor {gamma} (PPAR{gamma}) Expression and Sensitivity of Breast Cancer Cells to PPAR{gamma} Ligand Therapy. Clin. Cancer Res. 9: 3198-3203 [Abstract] [Full Text]  
• Trent, J. C., Valero, V., Booser, D. J., Esparza-Guerra, L. T., Ibrahim, N., Rahman, Z., Vernillet, L., Patel, S., David, C. L., Murray, J. L., Cristofanilli, M., Hortobagyi, G. N. (2003). A Phase I Study of Docetaxel Plus Cyclophosphamide in Solid Tumors followed by a Phase II Study as First-Line Therapy in Metastatic Breast Cancer. Clin. Cancer Res. 9: 2426-2434 [Abstract] [Full Text]  
• Delille, J.-P., Slanetz, P. J., Yeh, E. D., Halpern, E. F., Kopans, D. B., Garrido, L. (2003). Invasive Ductal Breast Carcinoma Response to Neoadjuvant Chemotherapy: Noninvasive Monitoring with Functional MR Imaging— Pilot Study. Radiology 228: 63-69 [Abstract] [Full Text]  
• Verma, S., Ilersich, A. L. (2003). Population-Based Pharmacoeconomic Model for Adopting Capecitabine/Docetaxel Combination Treatment for Anthracycline-Pretreated Metastatic Breast Cancer. The Oncologist 8: 232-240 [Abstract] [Full Text]  
• Courneya, K. S., Mackey, J. R., Bell, G. J., Jones, L. W., Field, C. J., Fairey, A. S. (2003). Randomized Controlled Trial of Exercise Training in Postmenopausal Breast Cancer Survivors: Cardiopulmonary and Quality of Life Outcomes. JCO 21: 1660-1668 [Abstract] [Full Text]  
• Valero, V., Hortobagyi, G. N. (2003). Are Anthracycline-Taxane Regimens the New Standard of Care in the Treatment of Metastatic Breast Cancer?. JCO 21: 959-962 [Full Text]  
• Esteva, F. J., Glaspy, J., Baidas, S., Laufman, L., Hutchins, L., Dickler, M., Tripathy, D., Cohen, R., DeMichele, A., Yocum, R. C., Osborne, C. K., Hayes, D. F., Hortobagyi, G. N., Winer, E., Demetri, G. D. (2003). Multicenter Phase II Study of Oral Bexarotene for Patients With Metastatic Breast Cancer. JCO 21: 999-1006 [Abstract] [Full Text]  
• Riggs, B. L., Hartmann, L. C. (2003). Selective Estrogen-Receptor Modulators -- Mechanisms of Action and Application to Clinical Practice. NEJM 348: 618-629 [Full Text]  
• Burger, H., Foekens, J. A., Look, M. P., Meijer-van Gelder, M. E., Klijn, J. G. M., Wiemer, E. A. C., Stoter, G., Nooter, K. (2003). RNA Expression of Breast Cancer Resistance Protein, Lung Resistance-related Protein, Multidrug Resistance-associated Proteins 1 and 2, and Multidrug Resistance Gene 1 in Breast Cancer: Correlation with Chemotherapeutic Response. Clin. Cancer Res. 9: 827-836 [Abstract] [Full Text]  
• Du, X. L., Key, C. R., Osborne, C., Mahnken, J. D., Goodwin, J. S. (2003). Discrepancy between Consensus Recommendations and Actual Community Use of Adjuvant Chemotherapy in Women with Breast Cancer. ANN INTERN MED 138: 90-97 [Abstract] [Full Text]  
• Du, X. L., Osborne, C., Goodwin, J. S. (2002). Population-Based Assessment of Hospitalizations for Toxicity From Chemotherapy in Older Women With Breast Cancer. JCO 20: 4636-4642 [Abstract] [Full Text]  
• Giordano, S. H., Booser, D. J., Murray, J. L., Ibrahim, N. K., Rahman, Z. U., Valero, V., Theriault, R. L., Rosales, M. F., Rivera, E., Frye, D., Ewer, M., Ordonez, N. G., Buzdar, A. U., Hortobagyi, G. N. (2002). A Detailed Evaluation of Cardiac Toxicity: A Phase II Study of Doxorubicin and One- or Three-Hour-Infusion Paclitaxel in Patients with Metastatic Breast Cancer. Clin. Cancer Res. 8: 3360-3368 [Abstract] [Full Text]  
• Modi, S., Panageas, K. S., Duck, E. T., Bach, A., Weinstock, N., Dougherty, J., Cramer, L., Hudis, C., Norton, L., Seidman, A. (2002). Prospective Exploratory Analysis of the Association Between Tumor Response, Quality of Life, and Expenditures Among Patients Receiving Paclitaxel Monotherapy for Refractory Metastatic Breast Cancer. JCO 20: 3665-3673 [Abstract] [Full Text]  
• Osoba, D., Slamon, D. J., Burchmore, M., Murphy, M. (2002). Effects on Quality of Life of Combined Trastuzumab and Chemotherapy in Women With Metastatic Breast Cancer. JCO 20: 3106-3113 [Abstract] [Full Text]  
• Rouzier, R., Extra, J.-M., Klijanienko, J., Falcou, M.-C., Asselain, B., Vincent-Salomon, A., Vielh, P., Bourstyn, E. (2002). Incidence and Prognostic Significance of Complete Axillary Downstaging After Primary Chemotherapy in Breast Cancer Patients With T1 to T3 Tumors and Cytologically Proven Axillary Metastatic Lymph Nodes. JCO 20: 1304-1310 [Abstract] [Full Text]  
• Toppmeyer, D., Seidman, A. D., Pollak, M., Russell, C., Tkaczuk, K., Verma, S., Overmoyer, B., Garg, V., Ette, E., Harding, M. W., Demetri, G. D. (2002). Safety and Efficacy of the Multidrug Resistance Inhibitor Incel (Biricodar; VX-710) in Combination with Paclitaxel for Advanced Breast Cancer Refractory to Paclitaxel. Clin. Cancer Res. 8: 670-678 [Abstract] [Full Text]  
• Cardoso, F., Di Leo, A., Lohrisch, C., Bernard, C., Ferreira, F., Piccart, M. J. (2002). Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades?. Ann Oncol 13: 197-207 [Abstract] [Full Text]  
• Keefe, D. L. (2002). The Cardiotoxic Potential of the 5-HT3 Receptor Antagonist Antiemetics: Is There Cause for Concern?. The Oncologist 7: 65-72 [Abstract] [Full Text]  
• Colleoni, M., Rocca, A., Sandri, M. T., Zorzino, L., Masci, G., Nole, F., Peruzzotti, G., Robertson, C., Orlando, L., Cinieri, S., Braud, F. d., Viale, G., Goldhirsch, A. (2002). Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 13: 73-80 [Abstract] [Full Text]  
• Canto, M. T., Anderson, W. F., Brawley, O. (2001). Geographic Variation in Breast Cancer Mortality for White and Black Women: 1986-1995. CA Cancer J Clin 51: 367-370 [Abstract] [Full Text]  
• Yang, X., Phillips, D. L., Ferguson, A. T., Nelson, W. G., Herman, J. G., Davidson, N. E. (2001). Synergistic Activation of Functional Estrogen Receptor (ER)-{alpha} by DNA Methyltransferase and Histone Deacetylase Inhibition in Human ER-{alpha}-negative Breast Cancer Cells. Cancer Res. 61: 7025-7029 [Abstract] [Full Text]  
• Shigeoka, Y., Itoh, K., Igarashi, T., Ishizawa, K., Saeki, T., Fujii, H., Minami, H., Imoto, S., Sasaki, Y. (2001). Clinical Effect of Irinotecan in Advanced and Metastatic Breast Cancer Patients Previously Treated with Doxorubicin- and Docetaxel-containing Regimens. Jpn J Clin Oncol 31: 370-374 [Abstract] [Full Text]  
• SHIMOYAMA, M., MURATA, Y., SUMI, K.-I., HAMAZOE, R., KOMURO, I. (2001). Docetaxel induced cardiotoxicity. Heart 86: 219-219 [Full Text]  
• Matsuda, K., Maruyama, H., Guo, F., Kleeff, J., Itakura, J., Matsumoto, Y., Lander, A. D., Korc, M. (2001). Glypican-1 Is Overexpressed in Human Breast Cancer and Modulates the Mitogenic Effects of Multiple Heparin-binding Growth Factors in Breast Cancer Cells. Cancer Res. 61: 5562-5569 [Abstract] [Full Text]  
• Davis, J. W. II, Lauer, F. T., Burdick, A. D., Hudson, L. G., Burchiel, S. W. (2001). Prevention of Apoptosis by 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) in the MCF-10A Cell Line: Correlation with Increased Transforming GrowthFactor {{alpha}} Production. Cancer Res. 61: 3314-3320 [Abstract] [Full Text]  
• Esteva, F. J., Valero, V., Pusztai, L., Boehnke-Michaud, L., Buzdar, A. U., Hortobagyi, G. N. (2001). Chemotherapy of Metastatic Breast Cancer: What to Expect in 2001 and Beyond. The Oncologist 6: 133-146 [Abstract] [Full Text]  
• Jassem, J., Pienkowski, T., Pluzanska, A., Jelic, S., Gorbunova, V., Mrsic-Krmpotic, Z., Berzins, J., Nagykalnai, T., Wigler, N., Renard, J., Munier, S., Weil, C. (2001). Doxorubicin and Paclitaxel Versus Fluorouracil, Doxorubicin, and Cyclophosphamide as First-Line Therapy for Women With Metastatic Breast Cancer: Final Results of a Randomized Phase III Multicenter Trial. JCO 19: 1707-1715 [Abstract] [Full Text]  
• Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., Baselga, J., Norton, L. (2001). Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2. NEJM 344: 783-792 [Abstract] [Full Text]  
• Taamma, A., Misset, J. L., Riofrio, M., Guzman, C., Brain, E., Lopez Lazaro, L., Rosing, H., Jimeno, J. M., Cvitkovic, E. (2001). Phase I and Pharmacokinetic Study of Ecteinascidin-743, a New Marine Compound, Administered as a 24-hour Continuous Infusion in Patients With Solid Tumors. JCO 19: 1256-1265 [Abstract] [Full Text]  
• Du, X., Goodwin, J. S. (2001). Patterns of Use of Chemotherapy for Breast Cancer in Older Women: Findings From Medicare Claims Data. JCO 19: 1455-1461 [Abstract] [Full Text]  
• Herndon, C. M., Arayath, J., Hallin, P. (2001). The role of tamoxifen in hospice: Pros and cons. AM J HOSP PALLIAT CARE 18: 133-134  
• Tong, A. W., Papayoti, M. H., Netto, G., Armstrong, D. T., Ordonez, G., Lawson, J. M., Stone, M. J. (2001). Growth-inhibitory Effects of CD40 Ligand (CD154) and Its Endogenous Expression in Human Breast Cancer. Clin. Cancer Res. 7: 691-703 [Abstract] [Full Text]  
• Ando, M., Watanabe, T., Nagata, K., Narabayashi, M., Adachi, I., Katsumata, N. (2001). Efficacy of Docetaxel 60 mg/m2 in Patients With Metastatic Breast Cancer According to the Status of Anthracycline Resistance. JCO 19: 336-342 [Abstract] [Full Text]  
• Fritz, P., Murdter, T. E., Eichelbaum, M., Siegle, I., Weissert, M., Zanger, U. M. (2001). Microsomal Epoxide Hydrolase Expression as a Predictor of Tamoxifen Response in Primary Breast Cancer: A Retrospective Exploratory Study With Long-Term Follow-Up. JCO 19: 3-9 [Abstract] [Full Text]  
• Yang, X., Ferguson, A. T., Nass, S. J., Phillips, D. L., Butash, K. A., Wang, S. M., Herman, J. G., Davidson, N. E. (2000). Transcriptional Activation of Estrogen Receptor {{alpha}} in Human Breast Cancer Cells by Histone Deacetylase Inhibition. Cancer Res. 60: 6890-6894 [Abstract] [Full Text]  
• KASISKE, B. L., VAZQUEZ, M. A., HARMON, W. E., BROWN, R. S., DANOVITCH, G. M., GASTON, R. S., ROTH, D., SCANDLING, J. D. JR., SINGER, G. G. (2000). Recommendations for the Outpatient Surveillance of Renal Transplant Recipients. J. Am. Soc. Nephrol. 11 : S1-S86 [Abstract] [Full Text]  
• Biswas, D. K., Cruz, A. P., Gansberger, E., Pardee, A. B. (2000). Epidermal growth factor-induced nuclear factor kappa B activation: A major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc. Natl. Acad. Sci. USA 97: 8542-8547 [Abstract] [Full Text]  
• Giuliano, A. E., Haigh, P. I., Brennan, M. B., Hansen, N. M., Kelley, M. C., Ye, W., Glass, E. C., Turner, R. R. (2000). Prospective Observational Study of Sentinel Lymphadenectomy Without Further Axillary Dissection in Patients With Sentinel Node-Negative Breast Cancer. JCO 18: 2553-2559 [Abstract] [Full Text]  
• Lonning, P. E., Bajetta, E., Murray, R., Tubiana-Hulin, M., Eisenberg, P. D., Mickiewicz, E., Celio, L., Pitt, P., Mita, M., Aaronson, N. K., Fowst, C., Arkhipov, A., di Salle, E., Polli, A., Massimini, G. (2000). Activity of Exemestane in Metastatic Breast Cancer After Failure of Nonsteroidal Aromatase Inhibitors: A Phase II Trial. JCO 18: 2234-2244 [Abstract] [Full Text]  
• Davis, J. W. II, Melendez, K., Salas, V. M., Lauer, F. T., Burchiel, S. W. (2000). 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) inhibits growth factor withdrawal-induced apoptosis in the human mammary epithelial cell line, MCF-10A. Carcinogenesis 21: 881-886 [Abstract] [Full Text]  
• Smith, I. C., Welch, A. E., Hutcheon, A. W., Miller, I. D., Payne, S., Chilcott, F., Waikar, S., Whitaker, T., Ah-See, A. K., Eremin, O., Heys, S. D., Gilbert, F. J., Sharp, P. F. (2000). Positron Emission Tomography Using [18F]-Fluorodeoxy-D-Glucose to Predict the Pathologic Response of Breast Cancer to Primary Chemotherapy. JCO 18: 1676-1688 [Abstract] [Full Text]  
• Dopp, J. M, Kolesar, J. M (1999). Risk of breast cancer associated with hormone replacement therapy. J Oncol Pharm Pract 5: 109-116 [Abstract]  
• Canizares, F., Salinas, J., las Heras, M. d., Diaz, J., Tovar, I., Martinez, P., Penafiel, R. (1999). Prognostic Value of Ornithine Decarboxylase and Polyamines in Human Breast Cancer: Correlation with Clinicopathologic Parameters. Clin. Cancer Res. 5: 2035-2041 [Abstract] [Full Text]  
• Cosman, F., Lindsay, R. (1999). Selective Estrogen Receptor Modulators: Clinical Spectrum. Endocr. Rev. 20: 418-434 [Abstract] [Full Text]  
• Browman, G. P. (1999). Science, Language, Intuition, and the Many Meanings of Quality of Life. JCO 17: 1651-1651 [Full Text]  
• Corcoran, T., Del Mastro, L., Venturini, M., Hortobagyi, G. N. (1999). Treatment of Breast Cancer. NEJM 340: 319-320 [Full Text]  
• Yamauchi, T., Yamauchi, N., Ueki, K., Sugiyama, T., Waki, H., Miki, H., Tobe, K., Matsuda, S., Tsushima, T., Yamamoto, T., Fujita, T., Taketani, Y., Fukayama, M., Kimura, S., Yazaki, Y., Nagai, R., Kadowaki, T. (2000). Constitutive Tyrosine Phosphorylation of ErbB-2 via Jak2 by Autocrine Secretion of Prolactin in Human Breast Cancer. J. Biol. Chem. 275: 33937-33944 [Abstract] [Full Text]  
• Chinnaiyan, A. M., Prasad, U., Shankar, S., Hamstra, D. A., Shanaiah, M., Chenevert, T. L., Ross, B. D., Rehemtulla, A. (2000). Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc. Natl. Acad. Sci. USA 97: 1754-1759 [Abstract] [Full Text]